Our findings suggest that calcium homeostasis dysregulation is involved in OS progression and that STC2 is a prioritized prognostic and functional candidate within this network. The findings suggest that STC2 may serve as a potential therapeutic target and candidate biomarker for OS, including in the context of predicted immunotherapy response, although this requires further validation.
Yao et al. (Thu,) studied this question.